Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy

Christopher J. Sweeney; Andrew Martin; Martin R. Stockler; Stephen Begbie; Kim N.; Simon Chowdhury; Xanthi Coskinas; Mark Frydenberg; Wendy Hague; Lisa G. Horvath; Anthony M. Joshua; Nicola Jane Lawrence; Gavin Marx; John McCaffrey; Ray McDermott; Margaret McJannett; Scott North; Francis Parnis; Wendy R. Parulekar; David Pook; M. Neil Reaume; Shahneen Sandhu; Alvin Tan; Thean Hsiang Tan; Alastair Thomson; Emily Tu; Francisco Vera-Badillo; Scott Williams; Sonia Yip; Alison Y. Zhang; Robert Zielinski; Ian D. Davis

doi:10.1016/j.eururo.2021.05.016

Related publications

Article2022

Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC).

Ian D. Davis, Andrew Martin, Robert Zielinski, Alastair Thomson, Thean Hsiang Tan, Shahneen Sandhu, M. Neil Reaume, David Pook, Francis Parnis, Scott North, Gavin Marx, John McCaffrey, Ray McDermott, Nicola Jane Lawrence, Lisa G. Horvath, Mark Frydenberg, Simon Chowdhury, Kim N., Martin R. Stockler, Christopher Sweeney

Article2025

8-year outcomes of enzalutamide (ENZA) versus a non-steroidal anti-androgen (NSAA) for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304).

Alison Yan Zhang, Ian D. Davis, Hayley Thomas, Ronan Andrew McLaughlin, Thean Hsiang Tan, David Pook, Gavin Marx, Robert Zielinski, Shahneen Sandhu, Alastair Thomson, M. Neil Reaume, Scott North, John McCaffrey, Ray McDermott, Nicola Jane Lawrence, Lisa G. Horvath, Simon Chowdhury, Kim N., Martin R. Stockler, Christopher Sweeney

Chapter in a book2024

Chemoresistance, Radioresistance, and Androgen Deprivation Therapy Resistance in Prostate Cancer

Samaneh Adelian, Amin Soltani, Michael R Hamblin

Article2024

Prognostic implications of PSA levels at 7 months in metastatic hormone-sensitive prostate cancer treated with enzalutamide: Landmark analysis of ENZAMET (ANZUP 1304).

Ronan Andrew Mc Laughlin, Hayley Thomas, Ian D. Davis, Robert Zielinski, Alastair Thomson, Thean Hsiang Tan, Shahneen Sandhu, M. Neil Reaume, David Pook, Francis Parnis, Scott North, Gavin Marx, John McCaffrey, Ray McDermott, Lisa G. Horvath, Mark Frydenberg, Simon Chowdhury, Kim N., Martin R. Stockler, Christopher Sweeney

Article2019

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

Ian D. Davis, Andrew Martin, Martin R. Stockler, Stephen Begbie, Kim N., Simon Chowdhury, Xanthi Coskinas, Mark Frydenberg, Wendy Hague, Lisa G. Horvath, Anthony M. Joshua, Nicola Jane Lawrence, Gavin Marx, John McCaffrey, Ray McDermott, Margaret McJannett, Scott North, Francis Parnis, Wendy R. Parulekar, David Pook, M. Neil Reaume, Shahneen Sandhu, Alvin Tan, Thean Hsiang Tan,